Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure

PHASE2CompletedINTERVENTIONAL
Enrollment

284

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Chronic Renal InsufficiencyDiabete MellitusCongestive Heart Failure
Interventions
DRUG

GE-145

GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.

Trial Locations (1)

08540

GE Healthcare, Princeton

Sponsors
All Listed Sponsors
collaborator

i3 Statprobe

INDUSTRY

collaborator

Medpace, Inc.

INDUSTRY

collaborator

Biomedical Systems

INDUSTRY

collaborator

Rules-Based Medicine, Inc.

INDUSTRY

lead

GE Healthcare

INDUSTRY